PajamaJedi recommends it. Is it the one PFE dropped like bad feesh and to do their own version? Didn't PTIE stuff fail a lab dissolution GI test? I don't believe PajamaJedi.
She was referring to soli beating moxi in port 3 and 4 orally. Here is the analyst question to your answer:
Carmen Eng, Jefferies - Analyst 
"And then one more, if I could -- sorry. So in the Solitaire IV study there are more PORTS III and IV patients compared to the Solitaire oral study. Do you expect to see a better outcome in the IV study?"
There are more port 3 in this IV study, because presumably they would need IV to begin therapy being sicker.
Or the big bad wolf, this isn't a paper tiger chinese company, to be blown about by a huff and a puff. I think he puffed on something pharmaceutical from CO "Puff the Magic Dragon". Tonight he will likely lite up again and start some rant and rave. pajamaJedi dreams
That pajamaJedi said this was way overpriced, such bad advice. He doesn't know how to value abx companies heading toward approval catalysts.
No patients on soli have generated C. Diff. Moxi they have. So you don't know why? TSRX I got in cheaply for buyout. You still didn't answer question of which company was selling $50 million flop antibiotic. BTW I made money on OPTR PDUFA.
Good point. Soli stops C Diff, thats why its not being seen in patients on soli. I posted article details above.
Soli stops C. Diff. Jeez, for a pharma veteran you need to back up your statements with facts as to why soli doesn't spawn C. Diff.. Learn to use literature to figure out that your statement is incorrect, before spouting off. "CEM-101 displayed a MIC50 of 0.12 µg/mL against C. difficile and 0.06 µg/mL against other Clostridia species."
Source: Progress in the Discovery of Treatments for C. difficile Infection: A Clinical and Medicinal Chemistry Review. Author(s): Lissa S. Tsutsumi, Yaw B. Owusu, Julian G. Hurdle and Dianqing Sun
Curr Top Med Chem. 2014; 14(1): 152–175.
All right, I want to know all these companies that flopped with under $50 million in sales. I have been in pharma industry for a long time PhD, so if you would kindly list these antibiotics companies that flopped, I would appreciate. I have been in CEMP since $9's. DRTX had a long acting vanco, company bought out after approval. TSRX had a better Zyvox, bought by CBST along with OPTR. CBST bought for $8 billion by MRK. So according to you for CBST why wasn't some big pharma all over them when their drugs were in Phase 3? CBST had only $1 billion in sales when purchased by MRK. There is a dearth in antibiotic development pipeline, GAIN Act is helping, and CEMP will go higher in spite of your not agreeing with what it might be worth.
Read this from my other post: Btechg wrote this I copied it for you: "GB and Australia just about banned fluouroquinolones because of side effects. If Europe is begging for soli it must be a big deal. These soli trials were not done in these countries because it was unethical in their eyes. Bye Bye Moxi."
Europe doesn't pay for many drugs, but they want soli, listen to cc. Also Japan progressing.
still bung, IV should give tighter results and soli is being given for 7 days in this trial vs. 5 days in oral. Moxi given for 7 days in both trials.
She also said in EU they want to stay in hospital 7 days because it is better than going home with better food and care. I like your way of thinking, still they measure early clinical response at 72 hours in all in intent to treat as primary outcome.